Introduction
Elopag 20 mg is identified as a medicine containing eltrombopag, an oral thrombopoietin receptor agonist. Eltrombopag acts on the thrombopoietin receptor to support the development of megakaryocytes, the bone marrow cells responsible for producing platelets.
Platelets are blood components that help the body form clots and control bleeding. In certain medical conditions, platelet counts may become abnormally low, increasing the risk of bruising or bleeding. Eltrombopag may be prescribed in selected patients to help increase platelet production.
Prescribing information is important because eltrombopag requires appropriate patient selection, individualized dosing and regular monitoring. Treatment decisions depend on the patient’s diagnosis, age, liver function, platelet count, other medicines and response to therapy.
Important product-specific note: The information on this page describes general medical information about eltrombopag. The complete, independently verified prescribing information for the specific Elopag 20 mg product has not been established here. Always consult the package leaflet supplied with the medicine and a qualified healthcare professional for product-specific instructions.
1. Medicine Identification
- Brand name: Elopag
- Strength identified: 20 mg
- Active ingredient: Eltrombopag
- Medicine category: Thrombopoietin receptor agonist
- Dosage form: Oral medicine; confirm the exact dosage form from the product packaging.
- Main therapeutic action: Supports platelet production.
- Route of administration: Oral, according to the prescribed product instructions.
- Prescription status: Follow the applicable prescription and dispensing requirements in your country.
The stated strength of 20 mg describes the amount of eltrombopag identified for this product. It does not establish the appropriate dose for every patient. The prescribed daily dose may differ according to the condition being treated and individual clinical factors.
2. Approved and Established Medical Uses
Eltrombopag is used for selected patients with certain conditions involving low platelet counts or impaired blood-cell production. The authorized indications differ between countries and may change as regulatory approvals are updated.
Chronic immune thrombocytopenia
Chronic immune thrombocytopenia (ITP) is an immune-related condition in which the body’s immune system destroys platelets or interferes with their production. Patients may experience easy bruising, small red or purple spots on the skin, nosebleeds, gum bleeding or other bleeding symptoms.
Eltrombopag may be prescribed for eligible patients with persistent or chronic ITP when other treatments have not provided an adequate response or when treatment is otherwise clinically appropriate.
The objective is to increase the platelet count to a level that helps reduce bleeding risk. The aim is not necessarily to make the platelet count normal.
Severe aplastic anemia
Severe aplastic anemia is a serious bone marrow disorder in which the bone marrow does not produce enough blood cells. This may lead to low red blood cells, white blood cells and platelets.
Eltrombopag may be used in specific severe aplastic anemia treatment settings. The appropriate treatment approach depends on the patient’s age, previous treatment, disease characteristics and the applicable clinical protocol.
Thrombocytopenia associated with chronic hepatitis C
In certain approved treatment settings, eltrombopag has been used for thrombocytopenia associated with chronic hepatitis C to help maintain platelet counts during interferon-based antiviral treatment.
This indication is dependent on the applicable country’s product authorization and treatment guidelines. It should not be assumed that eltrombopag is appropriate for every patient with hepatitis C or low platelets.
3. How Eltrombopag Works
Eltrombopag is a thrombopoietin receptor agonist. It interacts with the thrombopoietin receptor, also known as c-Mpl, which is involved in the development and maturation of platelet-producing cells.
Its main actions include:
- Binding to and activating the thrombopoietin receptor.
- Supporting the growth and development of megakaryocyte precursor cells.
- Promoting the maturation of megakaryocytes in the bone marrow.
- Supporting platelet production.
- Helping increase platelet counts in selected patients.
The response is not immediate and can vary between individuals. Treatment must be monitored because excessive platelet increases may contribute to thrombotic complications.
4. Dosage and Administration Information
Eltrombopag dosing must be individualized. The appropriate dose depends on the condition being treated, the patient’s age, liver function, platelet count, response to treatment and other clinical factors.
The fact that Elopag is identified as a 20 mg strength does not mean that 20 mg is the correct starting dose or daily dose for every indication.
General dosing considerations
A healthcare professional determines:
- The appropriate starting dose.
- Whether a dose adjustment is required.
- How frequently platelet counts should be checked.
- Whether treatment should be temporarily interrupted.
- Whether the medicine should be discontinued.
- The appropriate treatment duration.
Patients should not increase, reduce, stop or restart eltrombopag without medical advice.
How to take eltrombopag
Eltrombopag is an oral medicine. Follow the exact administration instructions supplied with the prescribed product.
For reference, the U.S. prescribing information for the reference product PROMACTA includes administration instructions concerning food and products containing polyvalent cations. These instructions should not automatically be treated as verified directions for Elopag unless confirmed by its own approved leaflet.
Food and mineral interactions
Calcium, iron, magnesium, aluminium and zinc can reduce eltrombopag absorption when taken too close to the medicine.
Products that may contain these minerals include:
- Calcium supplements.
- Iron supplements.
- Magnesium-containing antacids.
- Aluminium-containing antacids.
- Zinc supplements.
- Mineral-containing multivitamins.
- Certain fortified foods and beverages.
The U.S. reference-product instructions specify taking eltrombopag either without food or with a meal containing no more than 50 mg of calcium, and separating it from polyvalent-cation-containing products by at least two hours before or four hours after. Confirm the applicable instructions for the prescribed Elopag product with a pharmacist or doctor.
Missed dose
If a dose is missed, follow the instructions provided by the prescribing healthcare professional or the product leaflet. Do not take an additional dose to compensate for a missed dose unless specifically instructed.
5. Contraindications and Important Precautions
Before prescribing eltrombopag, a healthcare professional should review the patient’s medical history, current medicines and relevant laboratory results.
Liver problems
Eltrombopag can cause abnormalities in liver function tests and, in some patients, clinically significant liver injury.
Patients with existing liver disease may require additional assessment and closer monitoring. Liver function should be evaluated before and during treatment according to the applicable prescribing guidance.
History of blood clots
Eltrombopag can increase the risk of thrombotic or thromboembolic complications in some patients. These events may occur even when platelet counts are not extremely high.
Patients with a history of blood clots or other clotting risk factors should discuss these risks with their healthcare professional.
Excessive platelet increases
A platelet count that becomes too high may increase the risk of blood clots. The dose should be adjusted according to platelet-count monitoring and the relevant treatment guidelines.
Pregnancy and breastfeeding
Patients who are pregnant, planning pregnancy or breastfeeding should discuss eltrombopag with their healthcare professional before treatment. The potential benefits and risks must be assessed individually.
Children and older adults
The suitability and dose of eltrombopag in children and older adults depend on the indication, age, clinical condition and applicable product authorization. Do not assume that adult dosing is suitable for younger patients.
Other medical conditions
Tell the prescribing healthcare professional about:
- Liver or kidney problems.
- Previous blood clots.
- Cardiovascular disease.
- Bleeding disorders.
- Previous or current cancer.
- Pregnancy or breastfeeding.
- Any previous allergic reaction to eltrombopag or product ingredients.
6. Warnings Requiring Medical Attention
Some adverse effects associated with eltrombopag can be serious. Patients should understand the warning signs that require prompt medical assessment.
Liver injury
Possible warning signs include:
- Yellowing of the skin or eyes.
- Dark urine.
- Unusual tiredness.
- Pain in the upper right area of the abdomen.
- Loss of appetite.
- Unexplained nausea.
These symptoms should be reported promptly.
Blood clots
Seek urgent medical attention for possible symptoms of a blood clot, including:
- Sudden chest pain.
- Difficulty breathing.
- Sudden weakness or numbness.
- Painful swelling in one leg.
- Sudden changes in vision or speech.
- Severe or unusual abdominal pain.
These symptoms can have other causes, but they require urgent assessment.
Severe allergic reactions
A serious allergic reaction may cause swelling of the face, lips, tongue or throat, breathing difficulty, or a widespread severe rash. Emergency medical assistance is required if these symptoms occur.
Worsening bleeding
Although eltrombopag can increase platelet counts, it does not guarantee protection from bleeding. Report unusual bruising, persistent nosebleeds, blood in urine or stool, or other significant bleeding.
7. Side Effects
Like other prescription medicines, eltrombopag can cause side effects. Their frequency and severity vary among patients and depend on the condition being treated.
Commonly reported side effects
Possible side effects include:
- Nausea.
- Diarrhoea.
- Headache.
- Fatigue.
- Cough.
- Upper respiratory tract symptoms.
- Muscle pain.
- Back pain.
- Abdominal discomfort.
- Changes in liver function tests.
Not every patient experiences these effects. A healthcare professional should assess persistent, severe or worsening symptoms.
Serious side effects
Important serious risks include:
- Liver toxicity or liver injury.
- Thrombotic and thromboembolic events.
- Excessive platelet increases.
- Worsening thrombocytopenia after treatment interruption or discontinuation in some patients.
- Complications related to the underlying blood or bone marrow disorder.
Seek medical advice when serious symptoms develop. Do not attempt to manage potentially serious reactions by changing the dose yourself.
8. Drug and Food Interactions
Eltrombopag may interact with other medicines, supplements and foods. Tell the prescribing healthcare professional about everything being taken, including non-prescription medicines and herbal products.
Products containing polyvalent cations
Calcium, iron, magnesium, aluminium and zinc may reduce the absorption of eltrombopag. This includes some antacids, mineral supplements and multivitamins.
Other medicines
A healthcare professional or pharmacist should review all current medicines for potential interactions. Some medicines may affect liver function, bleeding risk or other clinical factors relevant to eltrombopag treatment.
Do not start a new prescription medicine, supplement or antacid without checking whether it can be taken safely with eltrombopag.
9. Monitoring During Treatment
Regular monitoring is an important part of eltrombopag treatment.
Platelet counts
Blood tests are used to assess platelet response and guide dose adjustments. Monitoring frequency depends on the indication, treatment stage and clinical response.
The goal is generally to achieve a platelet count sufficient to reduce bleeding risk, rather than to normalize the count unnecessarily.
Liver function
Liver function tests should be performed before and during treatment according to the applicable prescribing information. Abnormal results may require repeat testing, dose changes or discontinuation.
Other clinical assessments
Depending on the patient’s condition, the healthcare team may assess:
- Complete blood counts.
- Symptoms of bleeding.
- Symptoms of blood clots.
- Treatment response.
- Adverse reactions.
- Changes in the underlying disease.
Patients should attend scheduled appointments and complete recommended laboratory tests.
10. Use in Special Populations
Pregnancy
The safety of eltrombopag during pregnancy must be considered by a qualified healthcare professional. Patients should disclose pregnancy or plans to become pregnant before starting treatment.
Breastfeeding
Discuss breastfeeding with a doctor before using eltrombopag. The decision should consider the potential benefits of treatment and possible risks to the infant.
Children
Use in children depends on the specific indication, age and applicable authorization. Pediatric treatment requires specialist supervision and appropriate monitoring.
Older adults
Older patients may have additional medical conditions and may take several medicines. A healthcare professional should review these factors before and during treatment.
Patients with liver impairment
Liver impairment may affect treatment decisions and dosing. Appropriate assessment and monitoring are essential.
11. Overdose and Emergency Information
Taking more eltrombopag than prescribed may increase the risk of adverse effects, including excessive platelet increases and complications associated with abnormal clot formation.
If an overdose is suspected:
- Seek immediate medical advice.
- Contact local emergency services or a poison information service where available.
- Do not wait for symptoms to appear.
- Do not take another dose until a healthcare professional provides instructions.
- Keep the medicine packaging available for medical staff.
Do not attempt to treat a suspected overdose at home.
12. Storage and Handling
Follow the storage instructions printed on the Elopag packaging and supplied leaflet.
General medicine-handling precautions include:
- Keep the medicine in its original packaging when appropriate.
- Store it away from excessive heat and moisture.
- Keep it out of reach of children.
- Do not use it after the expiry date.
- Do not use damaged or improperly stored medicine.
- Ask a pharmacist how to dispose of unused or expired medicine safely.
The exact storage temperature and handling requirements should be confirmed from the product packaging.
13. Important Information for Patients
Patients taking eltrombopag should understand the following:
- Use the medicine only under appropriate medical supervision.
- Follow the prescribed dose and administration instructions.
- Do not change the dose without medical advice.
- Attend scheduled blood tests and follow-up appointments.
- Tell the healthcare professional about all medicines and supplements being used.
- Report symptoms that may indicate liver injury or blood clots.
- Follow instructions about food, calcium and mineral-containing products.
- Do not share the medicine with another person.
- Consult a healthcare professional before stopping treatment.
- Keep the medicine away from children and store it according to the package instructions.
14. Product-Specific Information and Verification
Elopag 20 mg is identified on this website as a product containing eltrombopag. However, the following product-specific details should be confirmed through the original packaging, approved product leaflet or relevant regulatory documentation:
- Manufacturer’s legal name.
- Marketing authorization holder.
- Manufacturing location.
- Country-specific regulatory authorization.
- Exact dosage form and inactive ingredients.
- Approved indications for the specific brand.
- Product-specific dosing and administration instructions.
- Product-specific storage requirements.
The general information about eltrombopag on this page should not be interpreted as proof that every indication or instruction applies to Elopag in every country.
Frequently Asked Questions About Elopag Prescribing Information
What is Elopag 20 mg?
Elopag 20 mg is identified as a product containing eltrombopag, a medicine belonging to the thrombopoietin receptor agonist class. Confirm the exact product details from its original packaging and approved leaflet.
What is eltrombopag prescribed for?
Depending on the applicable authorization, eltrombopag may be prescribed for selected patients with chronic immune thrombocytopenia, severe aplastic anemia or thrombocytopenia associated with chronic hepatitis C treatment.
Does Elopag increase platelet counts?
Eltrombopag stimulates the thrombopoietin receptor and supports platelet production. The extent of the response varies between patients.
Is Elopag 20 mg the correct dose for everyone?
No. The appropriate eltrombopag dose depends on the medical condition, patient characteristics, laboratory results and treatment response. The 20 mg strength does not establish a universal daily dose.
Should eltrombopag be taken with food?
Administration instructions depend on the applicable product information. Eltrombopag absorption can be reduced by calcium and other polyvalent cations. Follow the exact instructions supplied with the prescribed product.
What are the most important warnings?
Important warnings include liver injury, blood clots and excessive increases in platelet counts. Regular monitoring and medical supervision are essential.
Does eltrombopag require blood tests?
Yes. Platelet counts and liver function are important monitoring measures. The healthcare professional determines the appropriate testing schedule.
Can eltrombopag cause blood clots?
Yes. Thrombotic and thromboembolic events are recognized risks. Seek urgent medical assessment if symptoms suggest a possible blood clot.
Can I stop taking Elopag when my platelet count improves?
Do not stop treatment without medical advice. Platelet counts may change after treatment is interrupted or discontinued, and the appropriate plan depends on the underlying condition.
Is this page the official Elopag package leaflet?
No. This page provides general information about eltrombopag. It does not replace the official product leaflet, approved prescribing information or advice from a qualified healthcare professional.
Medical Disclaimer
This page is provided for general educational and informational purposes. It is not a substitute for professional medical advice, diagnosis, treatment or the official prescribing information supplied with a medicine.
Elopag-specific regulatory status, manufacturer information, approved indications, dosage instructions and storage requirements have not been independently verified for this page. General information about eltrombopag and reference-product instructions may differ from the approved information for a particular brand or country.
Always consult a qualified healthcare professional before starting, changing or stopping eltrombopag. Follow the product-specific package leaflet and local prescribing requirements. Seek urgent medical care for severe allergic reactions, symptoms of blood clots, serious bleeding or possible liver injury.
References
- U.S. Food and Drug Administration (FDA). PROMACTA (eltrombopag) Prescribing Information.
- DailyMed. Eltrombopag and PROMACTA drug labeling information.
- U.S. National Library of Medicine. Clinical drug information for eltrombopag.
- Relevant national regulatory product information and approved patient leaflets for eltrombopag.
- Published clinical guidance concerning immune thrombocytopenia and severe aplastic anemia.
Editorial note: Confirm all brand-specific statements against the current approved Elopag product documentation before publication or use in clinical decision-making.